The results presented in our study, which suggest that the relative protein level of caveolin-1 in plasma-derived Exos is higher in patients with high initial PSA values, in patients with clinical T3 or T4 stages, and in PCa patients with a high risk of cancer progression, are consistent with the presumed oncogenic effect of this protein and previous findings, including those mentioned above. Here, CAV1 is linked to posterior cortical atrophy.